Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Share-based Compensation: 2014-2025

Historic Share-based Compensation for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $3.4 million.

  • Coherus Oncology's Share-based Compensation fell 50.66% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year decrease of 36.16%. This contributed to the annual value of $27.8 million for FY2024, which is 35.51% down from last year.
  • Per Coherus Oncology's latest filing, its Share-based Compensation stood at $3.4 million for Q3 2025, which was down 37.48% from $5.4 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Share-based Compensation high stood at $16.9 million for Q1 2021, and its period low was $3.4 million during Q3 2025.
  • Over the past 3 years, Coherus Oncology's median Share-based Compensation value was $7.2 million (recorded in 2024), while the average stood at $7.7 million.
  • In the last 5 years, Coherus Oncology's Share-based Compensation surged by 76.70% in 2021 and then crashed by 50.66% in 2025.
  • Quarterly analysis of 5 years shows Coherus Oncology's Share-based Compensation stood at $10.9 million in 2021, then increased by 7.13% to $11.7 million in 2022, then fell by 7.91% to $10.8 million in 2023, then plummeted by 40.88% to $6.4 million in 2024, then slumped by 50.66% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $5.4 million for Q2 2025, and $5.4 million during Q1 2025.